Please login to the form below

Not currently logged in


This page shows the latest Galapagos news and features for those working in and with pharma, biotech and healthcare.

J&J takes option on Theravance’s JAK drug in $1bn deal

J&J takes option on Theravance’s JAK drug in $1bn deal

partner Galapagos, which is developing filgotinib with new collaborator Gilead.

Latest news

More from news
Approximately 4 fully matching, plus 32 partially matching documents found.

Latest Intelligence

  • Deal Watch May 2016 Deal Watch May 2016

    271. Galapagos/ AbbVie. Agreement extension. Cystic fibrosis alliance for development of a triple combination therapy; increase in milestones from $350m to $600m.

  • Deal Watch December 2015 Deal Watch December 2015

    therapy areas such as oncology and, this month inflammatory disease, following the licensing deal with Galapagos for over $2bn. ... Galapagos (NL). Gilead. Collaboration. licence. JAK1-selective inhibitor, filgotinib in phase II for RA and Crohn's

  • Deal Watch table for March 2014 Deal Watch table for March 2014

    195+. Galapagos/ Charles River. Acquisition of CRO business. Drug discovery services business.

  • Pharma deals during March 2014 Pharma deals during March 2014

    Galapagos decided to sell its BioFocus and Argenta drug discovery service divisions to Charles River during the month so that it could focus on being an R&D company and use

  • Pharma deals during September 2013 Pharma deals during September 2013

    This is not AbbVie's only insurance policy against Humira's patent expiry; it already established an RA collaboration with another Belgian company, Galapagos, in February 2012. ... AbbVie paid an upfront fee of $45m with Galapagos eligible to receive a

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...